A L Pozniak

Summary

Affiliation: Chelsea and Westminster Hospital
Country: UK

Publications

  1. ncbi request reprint Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
    Anton Pozniak
    HIV Unit, St Stephens Centre, Chelsea and Westminster Hospital, London, UK Electronic address
    Lancet Infect Dis 14:590-9. 2014
  2. doi request reprint HIV-associated neurocognitive disease: case studies and suggestions for diagnosis and management in different patient subgroups
    Anton Pozniak
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 19:1-13. 2014
  3. pmc Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
    Carlo Torti
    University of Brescia, Italy
    BMC Infect Dis 11:23. 2011
  4. pmc Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept(R), Roche): overview
    Anton Pozniak
    Pharmaceuticals Division, Hoffmann La Roche, Nutley, NJ, USA
    AIDS Res Ther 6:18. 2009
  5. ncbi request reprint Tenofovir: what have over 1 million years of patient experience taught us?
    A Pozniak
    Chelsea and Westminster Hospital, Department of HIV GU Medicine, London, UK
    Int J Clin Pract 62:1285-93. 2008
  6. doi request reprint Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2
    Anton Pozniak
    Chelsea and Westminster Hospital, London, UK
    AIDS Res Hum Retroviruses 24:1275-80. 2008
  7. doi request reprint Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial
    Anton L Pozniak
    Chelsea and Westminster NHS Foundation Trust and PKR SSR, London, UK
    AIDS 24:55-65. 2010
  8. doi request reprint Investigational agents for salvage
    Anton L Pozniak
    HIV Services, St Stephen s Centre, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
    Curr Opin HIV AIDS 4:524-30. 2009
  9. ncbi request reprint BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005
    A L Pozniak
    Chelsea and Westminster NHS Healthcare Trust, London, UK
    HIV Med 6:62-83. 2005
  10. ncbi request reprint British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy
    A Pozniak
    Chelsea and Westminster Hospital, London, UK
    HIV Med 4:1-41. 2003

Detail Information

Publications12

  1. ncbi request reprint Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
    Anton Pozniak
    HIV Unit, St Stephens Centre, Chelsea and Westminster Hospital, London, UK Electronic address
    Lancet Infect Dis 14:590-9. 2014
    ..We assessed the non-inferiority of such a switch compared with continuation of an NNRTI-containing regimen...
  2. doi request reprint HIV-associated neurocognitive disease: case studies and suggestions for diagnosis and management in different patient subgroups
    Anton Pozniak
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 19:1-13. 2014
    ..In this review, we discuss a series of case studies that address some of the challenges presented by the diagnosis and management of HIV-associated neurocognitive impairment in different patient types. ..
  3. pmc Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
    Carlo Torti
    University of Brescia, Italy
    BMC Infect Dis 11:23. 2011
    ..Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce...
  4. pmc Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept(R), Roche): overview
    Anton Pozniak
    Pharmaceuticals Division, Hoffmann La Roche, Nutley, NJ, USA
    AIDS Res Ther 6:18. 2009
    ..These findings are potentially relevant to >40 marketed drugs that are mesylate salts...
  5. ncbi request reprint Tenofovir: what have over 1 million years of patient experience taught us?
    A Pozniak
    Chelsea and Westminster Hospital, Department of HIV GU Medicine, London, UK
    Int J Clin Pract 62:1285-93. 2008
    ..This article reviews the development of tenofovir, including pivotal studies that have influenced HIV clinical practice...
  6. doi request reprint Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2
    Anton Pozniak
    Chelsea and Westminster Hospital, London, UK
    AIDS Res Hum Retroviruses 24:1275-80. 2008
    ..Darunavir/r 600/100 mg twice daily showed efficacy benefits over CPI use regardless of viral susceptibility at baseline, FC to darunavir or boosting type in a population of treatment-experienced HIV-infected patients...
  7. doi request reprint Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial
    Anton L Pozniak
    Chelsea and Westminster NHS Foundation Trust and PKR SSR, London, UK
    AIDS 24:55-65. 2010
    ..The week 96 analysis of TMC278-C204, a large dose-ranging study of TMC278 in treatment-naive HIV-1-infected patients, is presented...
  8. doi request reprint Investigational agents for salvage
    Anton L Pozniak
    HIV Services, St Stephen s Centre, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
    Curr Opin HIV AIDS 4:524-30. 2009
    ..This review will examine some of the compounds that may have a role to play in highly experienced patients in the future...
  9. ncbi request reprint BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005
    A L Pozniak
    Chelsea and Westminster NHS Healthcare Trust, London, UK
    HIV Med 6:62-83. 2005
  10. ncbi request reprint British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy
    A Pozniak
    Chelsea and Westminster Hospital, London, UK
    HIV Med 4:1-41. 2003
  11. ncbi request reprint The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients
    Y Gilleece
    Chelsea and Westminster Hospital, London, UK
    HIV Med 4:305-10. 2003
    ..We assessed phenotypic and genotypic resistance in ZDV-naive patients with virological failure on stavudine (d4T)-containing regimens, with particular reference to potential cross-resistance between d4T and ZDV...
  12. ncbi request reprint The radiology of IRIS (immune reconstitution inflammatory syndrome) in patients with mycobacterial tuberculosis and HIV co-infection: Appearances in 11 patients
    G Rajeswaran
    Department of Radiology, Chelsea and Westminster Hospital, London, UK
    Clin Radiol 61:833-43. 2006
    ..To determine the radiological manifestations of IRIS (immune reconstitution inflammatory syndrome) in patients with HIV and mycobacterium tuberculosis co-infection, in the context of their demographic and clinical data...